Author:
Kothari J,Foley M,Peggs K S,Mackenzie S,Thomson K,Morris E,Ardeshna K M,Virchis A E,Linch D C,Lambert J
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Reference13 articles.
1. Gorin NC, Najman A, Douay L, Salmon C, David R, Stachowiak J et al. Autologous bone marrow transplantation in the treatment of poor prognosis non-Hodgkin's lymphomas. Eur J Cancer Clin Oncol 1984; 20: 217–2225.
2. Gorin NC, Najman A, Douay L, Salmon C, David R, Stachowiak J et al. Non-Hodgkin's malignant lymphoma. Therapeutic value of autologous bone marrow transplantation. Presse Med 1983; 12: 1917–1923.
3. Alessandrino EP, Bernasconi P, Colombo A, Caldera D, Martinelli G, Vitulo P et al. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies. Bone Marrow Transplant 2000; 25: 309–313.
4. Musso M, Scalone R, Marcacci G, Lanza F, Di Renzo N, Cascavilla N et al. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transplant 2010; 45: 1147–1153.
5. Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 2011; 118: 3419–3425.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献